A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...

Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.

Two U.S. Food and Drug Administration (FDA)-approved drugs for treating prostate cancer may also be effective against acute ...

Oncologists and urologists identified several barriers to treatment intensification for metastatic castration-sensitive ...

Anti-androgen drugs block androgen hormones, such as testosterone. People can use them for many purposes, like slowing prostate cancer and minimizing the masculinizing effects of certain hormones.

The EMA’s assessment confirms the treatment matches the reference drug in quality and performance, potentially expanding ...

Only the secretory epithelial cells, which contain a surface androgen receptor, undergo apoptosis (programmed cell death) with AD. 17, 18 The clonal selection hypothesis advanced by Isaacs and Coffey ...

Cancer cells differentiate along specific lineages that largely determine their clinical and biologic behavior. Distinct cancer phenotypes from different cells and organs likely result from unique ...

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy.

First, an anchor point: male pattern hair loss (androgenetic alopecia, AGA) is primarily genetic and androgen-driven. Diet ...